Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

61. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis 27715439 2016 10 07 2017 03 16 1933-0693 2016 Oct 07 Journal of neurosurgery J. Neurosurg. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. 1-11 10.3171/2016.5.JNS152900 OBJECTIVE The efficacy of statin (...) therapy in treating aneurysmal subarachnoid hemorrhage (SAH) remains controversial. In this meta-analysis, the authors investigated whether statin treatment significantly reduced the incidence of cerebral vasospasm and delayed neurological deficits, promoting a better outcome after aneurysmal SAH. METHODS A literature search of the PubMed, Ovid, and Cochrane Library databases was performed for randomized controlled trials (RCTs) and prospective cohort studies investigating the effect of statin

EvidenceUpdates2016

62. PCSK9 Inhibitors: Who Could Need More than a Statin?

PCSK9 Inhibitors: Who Could Need More than a Statin? PCSK9 Inhibitors: Who Could Need More than a Statin? | Clinical Correlations PCSK9 Inhibitors: Who Could Need More than a Statin? October 5, 2016 By Rhodes Hambrick Peer Reviewed The atherosclerotic cardiovascular disease (ASCVD) risk associated with hyperlipidemia (HLD), readily of the mid-20 th century, has been the target of innumerable attempted pharmacologic interventions ever since. One class of agents, the HMG-CoA reductase inhibitors (...) , or statins, became – and have remained 2 – the gold standard for managing HLD-associated ASCVD risk in the setting of the remarkably favorable findings of multiple studies in the 1990s. 3-5 While other agents, including niacin, fish oil, and fibrates, have been demonstrated to have favorable effects on some combination of LDL, HDL, and triglycerides, only statins have been conclusively proven to be of consistent, predictable benefit in reducing ASCVD-related morbidity and mortality. That said, 6 in which

Clinical Correlations2016

63. Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial

Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial 27612487 2016 09 10 2017 03 15 1525-1497 32 3 2017 Mar Journal of general internal medicine J Gen Intern Med Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial. 256-261 10.1007/s11606-016-3858-0 Simple nudges such as reminders and feedback reports to either a patient or a partner may facilitate improved medication adherence. To test (...) the impact of a pill bottle used to monitor adherence, deliver a daily alarm, and generate weekly medication adherence feedback reports on statin adherence. Three-month, three-arm randomized clinical trial (ClinicalTrials.gov identifier: NCT02480530). One hundred and twenty-six veterans with known coronary artery disease and poor adherence (medication possession ratio <80 %). Patients were randomized to one of three groups: (1) a control group (n = 36) that received a pill-monitoring device

EvidenceUpdates2016

64. Statin withdrawal in people with dementia.

Statin withdrawal in people with dementia. BACKGROUND: There are approximately 24 million people worldwide with dementia; this is likely to increase to 81 million by 2040. Dementia is a progressive condition, and usually leads to death eight to ten years after first symptoms. End-of-life care should emphasise treatments that optimise quality of life and physicians should minimise unnecessary or non-beneficial interventions. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (...) inhibitors; they have become the cornerstone of pharmacotherapy for the management of hypercholesterolaemia but their ability to provide benefit is unclear in the last weeks or months of life. Withdrawal of statins may improve quality of life in people with advanced dementia, as they will not be subjected to unnecessary polypharmacy or side effects. However, they may help to prevent further vascular events in people of advanced age who are at high risk of such events. OBJECTIVES: To evaluate the effects

Cochrane2016

65. Interpretation of the evidence for the efficacy and safety of statin therapy.

Interpretation of the evidence for the efficacy and safety of statin therapy. This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect (...) a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend

Lancet2016

66. Statins for aortic valve stenosis.

Statins for aortic valve stenosis. BACKGROUND: Aortic valve stenosis is the most common type of valvular heart disease in the USA and Europe. Aortic valve stenosis is considered similar to atherosclerotic disease. Some studies have evaluated statins for aortic valve stenosis. OBJECTIVES: To evaluate the effectiveness and safety of statins in aortic valve stenosis. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS - IBECS, Web (...) of Science and CINAHL Plus. These databases were searched from their inception to 24 November 2015. We also searched trials in registers for ongoing trials. We used no language restrictions. SELECTION CRITERIA: Randomised controlled clinical trials (RCTs) comparing statins alone or in association with other systemic drugs to reduce cholesterol levels versus placebo or usual care. DATA COLLECTION AND ANALYSIS: Primary outcomes were severity of aortic valve stenosis (evaluated by echocardiographic criteria

Cochrane2016

67. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study

A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study 27561760 2016 08 26 2016 08 26 1558-3597 68 9 2016 Aug 30 Journal of the American College of Cardiology J. Am. Coll. Cardiol. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. 881-91 10.1016/j.jacc.2016.05.084 S0735-1097(16)33608-7 The 2013 American College of Cardiology (ACC)/American Heart (...) Association (AHA) guidelines recommend primary prevention with statins for individuals with ≥7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD). Everyone living long enough will become eligible for risk-based statin therapy due to age alone. This study sought to personalize ACC/AHA risk-based statin eligibility using noninvasive assessment of subclinical atherosclerosis. In 5,805 BioImage participants without known ASCVD at baseline, those with ≥7.5% 10-year ASCVD risk were down

EvidenceUpdates2016

68. Statin Use and Survival After Acute Kidney Injury

Statin Use and Survival After Acute Kidney Injury 29142930 2018 11 13 2468-0249 1 4 2016 Nov Kidney international reports Kidney Int Rep Statin Use and Survival After Acute Kidney Injury. 279-287 10.1016/j.ekir.2016.08.009 The incidence of acute kidney injury (AKI) in hospitalized patients is rising, and survivors are at high risk for cardiovascular events and mortality. Effective strategies that improve long-term outcomes of AKI are unknown. A retrospective cohort study was performed between (...) 2008 and 2011. All subjects were followed until 31 March 2013, with a minimum follow-up of 2 years. Participants were adults 18 years of age or older, who developed AKI during a hospitalization and had chronic kidney disease (CKD) following discharge (n = 19,707 mean age 69.9 years, mean postdischarge estimated glomerular filtration rate (eGFR) 43.0 ml/min/1.73 m 2 ). Exposure to statins was examined prior to the index hospitalization as well as within 2 years following hospital discharge

Kidney international reports2016 Full Text: Link to full Text with Trip Pro

69. Does co-enzyme Q10 reduce statin-related muscle pain?

Does co-enzyme Q10 reduce statin-related muscle pain? Does co-enzyme Q10 reduce statin-related muscle pain? » Morsels of Evidence Search Evidence based medicine for general practitioners « » Aug 08 Does co-enzyme Q10 reduce statin-related muscle pain? Categories: , , , , , by Journal reference: Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015 Jan;90(1):24-34. Link: Published: January (...) 2015 Evidence cookie says… The effect of CoQ10 on muscle pain in people on statin therapy is uncertain. The research evidence is of limited quality and inconsistent. The range of best estimates includes no effect. CoQ10 cannot be recommended as a matter of routine supplementation to prevent muscle pain in people taking statins. Clinical scenario Recently, a member of the GPs Down Under online discussion group described a situation where their patient who was prescribed a statin, was recommended

Morsels of Evidence2016

70. Statins for age-related macular degeneration.

Statins for age-related macular degeneration. BACKGROUND: Age-related macular degeneration (AMD) is a progressive, late-onset disorder of the macula affecting central vision. It is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown that AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD. OBJECTIVES: The objective (...) of this review was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2016), EMBASE (January 1980 to March 2016), Latin

Cochrane2016

71. Are statins effective for primary prevention of CVD?

Are statins effective for primary prevention of CVD? Are statins effective for primary prevention of CVD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Are statins effective for primary prevention of CVD? View/ Open Date 2016-05 Format Metadata Abstract Are statins effective for primary prevention of CVD? Evidence (...) -Based Answer: Statin use is effective in lowering rates of cardiovascular disease (CVD) events (stroke and myocardial infarction [MI]) and all-cause mortality in adult men and women without prior history of CVD events, including in those with low (less than 10% 5-year) cardiovascular risk (SOR: A, systematic reviews of RCTs). URI Part of Citation Evidence-Based Practice 19, no. 5 (2016): 7-8 Collections hosted by hosted by

Evidence Based Practice 2016

72. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins.

Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. 27438317 2016 07 21 2017 02 03 2380-6591 1 4 2016 Jul 01 JAMA cardiology JAMA Cardiol Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. 413-23 10.1001/jamacardio.2016.0605 Inflammation may contribute (...) was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease. Salsalate (3.5 g/d) or placebo orally over 30 months. The primary outcome was progression of noncalcified coronary artery plaque assessed by multidetector computed tomographic angiography. Secondary outcomes were other measures of safety and efficacy. Two hundred fifty

JAMA cardiology2016

73. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. OBJECTIVES: To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. DESIGN: Prospective open cohort study. SETTING: 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. PARTICIPANTS: Incident (...) statin users aged 25-84 years identified between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. MAIN OUTCOME MEASURES: Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who

BMJ2016

74. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data.

Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. OBJECTIVE: To quantify how a period of intense media coverage of controversy over the risk:benefit balance of statins affected their use. DESIGN: Interrupted time series analysis of prospectively collected electronic data from primary care. SETTING: Clinical Practice Research Datalink (CPRD) in the United Kingdom. PARTICIPANTS: Patients newly eligible for or currently taking (...) statins for primary and secondary cardiovascular disease prevention in each month in January 2011-March 2015. MAIN OUTCOME MEASURES: Adjusted odds ratios for starting/stopping taking statins after the media coverage (October 2013-March 2014). RESULTS: There was no evidence that the period of high media coverage was associated with changes in statin initiation among patients with a high recorded risk score for cardiovascular disease (primary prevention) or a recent cardiovascular event (secondary

BMJ2016

75. Does treatment with nondaily statin dosing reduce cardiovascular risk?

Does treatment with nondaily statin dosing reduce cardiovascular risk? Does treatment with nondaily statin dosing reduce cardiovascular risk? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does treatment with nondaily statin dosing reduce cardiovascular risk? View/ Open Date 2016-01 Format Metadata Abstract Does (...) treatment with nondaily statin dosing reduce cardiovascular risk? Evidence-Based Answer: Nondaily statin dosing (weekly or alternate-day dosing) results in greater lowering of low-density lipoprotein cholesterol (LDL-C) and LDL-C goal achievement compared with statin discontinuation and no difference in LDL-C goal achievement compared with daily dosing (SOR: C, RCT and nonrandomized trials of disease-oriented outcomes). Nondaily statins are recommended as an option for patients who have been unable

Evidence Based Practice 2016

76. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 27039291 2016 04 20 2016 05 01 2016 10 17 1538-3598 315 15 2016 Apr 19 JAMA JAMA Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 1580-90 10.1001/jama.2016.3608 Muscle-related statin intolerance is reported by 5% to 20% of patients. To identify patients (...) with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab. Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo

JAMA2016

77. More HOPE for Prevention with Statins.

More HOPE for Prevention with Statins. More HOPE for Prevention with Statins. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27039666 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 26;374(21):2085-7. doi: 10.1056/NEJMe1603504. Epub 2016 Apr 2. More HOPE for Prevention with Statins. 1 , 1 . 1 From the Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN (W.C.C.); and the Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (D.C.G.). Comment in [N Engl J Med. 2016] Comment

NEJM2016

78. Statin-Associated Autoimmune Myopathy.

Statin-Associated Autoimmune Myopathy. Statin-Associated Autoimmune Myopathy. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26886523 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Feb 18;374(7):664-9. doi: 10.1056/NEJMra1515161. Statin-Associated Autoimmune Myopathy. . PMID: 26886523 DOI: [Indexed for MEDLINE] Publication type MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed Simple NCBI Directory Getting

NEJM2016

79. Risk of Congenital Malformations With Statin Therapy During the First Trimester of Pregnancy

Risk of Congenital Malformations With Statin Therapy During the First Trimester of Pregnancy "Risk of Congenital Malformations With Statin Therapy During the First " by Alexander E. Hoffman < > > > > > Title Author Date of Award Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Brent Norris, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background Statins are the most common and effective drug used (...) to treat hyperlipidemia. Based on animal studies showing potential teratogenic effects at high doses, statins are contraindicated in pregnancy due to concern that they would disrupt cholesterol biosynthesis for the fetus. This review evaluates the current evidence of harm caused by statins when taken within the first trimester of pregnancy. Methods An exhaustive literature search was conducted in June 2015 using MEDLINE-Ovid, CINAHL, Evidence-Based Medicine Reviews Multifile, and Web of Sciences

Pacific University EBM Capstone Project2016

80. Among Adult Cancer Survivors Treated With Anthracycline Chemotherapies, Concurrent Statin Therapy May Reduce Their Decline in Left Ventricular Dysfunction

Among Adult Cancer Survivors Treated With Anthracycline Chemotherapies, Concurrent Statin Therapy May Reduce Their Decline in Left Ventricular Dysfunction "Among Adult Cancer Survivors Treated With Anthracycline Chemotherapies" by Mariah McGaffey < > > > > > Title Author Date of Award Spring 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers Rights . Abstract Background: Anthracycline chemotherapies are used (...) to treat a wide variety of malignancies. A study by Von Hoff et al showed that 2.2% of patients previously treated with anthracycline chemotherapy were later diagnosed with heart failure. A more recent study by Smain, et al, showed that 26% of patients receiving higher doses of anthracycline were later diagnosed with heart failure. Statins have been shown to have properties that may allow them to be cardioprotective. Animal research performed by Henninger et al suggests that statin therapy is

Pacific University EBM Capstone Project2016